Sickle cell retinopathy (SCR) is the most important ocular manifestation in sickle cell disease (SCD). Retinal tissue is highly sensible to vaso-occlusion and hypoxia observed in SCR pathophysiology, with consequent vessel remodeling and ultimately neovascularization in its proliferative form. Severe cases are followed by vitreous hemorrhage and retinal detachment, with 10–20% of vision loss in affected eyes. Current treatment options such as anti-VEGF (Vascular Endothelial Growth Factor) injections and laser photocoagulation are based on other proliferative retinopathies, without pre-clinical
This is a source preview. Continue at the original source to read more.
Open original source ↗